Sanofi Posts 4Q Showing Continued Shift Toward Specialty Care Drugs as Shares Look Undervalued
Sanofi reported fourth-quarter results slightly below both our and consensus' earnings projections, but we don't expect any major fair value estimate changes based on the minor underperformance. We continue to view the stock as undervalued as the investment community appears to underappreciate the firm's transformation from a focus in primary care toward specialty care where drug pricing power is stronger and operating margins are higher. Sanofi's current and growing position in areas of critica...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.